Literature DB >> 29916309

Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity.

Carlo Lancia1, Cristian Spitoni2,3, Jakob Anninga4, Jeremy Whelan5, Matthew R Sydes6, Gordana Jovic6, Marta Fiocco1,7.   

Abstract

Marginal structural models are causal models designed to adjust for time-dependent confounders in observational studies with dynamically adjusted treatments. They are robust tools to assess causality in complex longitudinal data. In this paper, a marginal structural model is proposed with an innovative dose-delay joint-exposure model for Inverse-Probability-of-Treatment Weighted estimation of the causal effect of alterations to the therapy intensity. The model is motivated by a precise clinical question concerning the possibility of reducing dosages in a regimen. It is applied to data from a randomised trial of chemotherapy in osteosarcoma, an aggressive primary bone-tumour. Chemotherapy data are complex because their longitudinal nature encompasses many clinical details like composition and organisation of multi-drug regimens, or dynamical therapy adjustments. This manuscript focuses on the clinical dynamical process of adjusting the therapy according to the patient's toxicity history, and the causal effect on the outcome of interest of such therapy modifications. Depending on patients' toxicity levels, variations to therapy intensity may be achieved by physicians through the allocation of either a reduction or a delay of the next planned dose. Thus, a negative feedback is present between exposure to cytotoxic agents and toxicity levels, which acts as time-dependent confounders. The construction of the model is illustrated highlighting the high complexity and entanglement of chemotherapy data. Built to address dosage reductions, the model also shows that delays in therapy administration should be avoided. The last aspect makes sense from the cytological point of view, but it is seldom addressed in the literature.

Entities:  

Keywords:  Causal inference; bivariate exposure; marginal structural models; osteosarcoma; therapy delay

Mesh:

Year:  2018        PMID: 29916309      PMCID: PMC6728750          DOI: 10.1177/0962280218780619

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  23 in total

1.  Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Authors:  J M Robins; D M Finkelstein
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

2.  Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.

Authors:  Sjw Willems; A Schat; M S van Noorden; M Fiocco
Journal:  Stat Methods Med Res       Date:  2016-03-17       Impact factor: 3.021

3.  A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods.

Authors:  J Robins
Journal:  J Chronic Dis       Date:  1987

Review 4.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?

Authors:  Jakob K Anninga; Hans Gelderblom; Marta Fiocco; Judith R Kroep; Antoni H M Taminiau; Pancras C W Hogendoorn; R Maarten Egeler
Journal:  Eur J Cancer       Date:  2011-06-22       Impact factor: 9.162

5.  Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup.

Authors:  I J Lewis; S Weeden; D Machin; D Stark; A W Craft
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

6.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

7.  The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.

Authors:  J S Wunder; G Paulian; A G Huvos; G Heller; P A Meyers; J H Healey
Journal:  J Bone Joint Surg Am       Date:  1998-07       Impact factor: 5.284

8.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

Authors:  J S Whelan; S S Bielack; N Marina; S Smeland; G Jovic; J M Hook; M Krailo; J Anninga; T Butterfass-Bahloul; T Böhling; G Calaminus; M Capra; C Deffenbaugh; C Dhooge; M Eriksson; A M Flanagan; H Gelderblom; A Goorin; R Gorlick; G Gosheger; R J Grimer; K S Hall; K Helmke; P C W Hogendoorn; G Jundt; L Kager; T Kuehne; C C Lau; G D Letson; J Meyer; P A Meyers; C Morris; H Mottl; H Nadel; R Nagarajan; R L Randall; P Schomberg; R Schwarz; L A Teot; M R Sydes; M Bernstein
Journal:  Ann Oncol       Date:  2014-11-24       Impact factor: 32.976

9.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Authors:  Stefan S Bielack; Sigbjørn Smeland; Jeremy S Whelan; Neyssa Marina; Gordana Jovic; Jane M Hook; Mark D Krailo; Mark Gebhardt; Zsuzsanna Pápai; James Meyer; Helen Nadel; R Lor Randall; Claudia Deffenbaugh; Rajaram Nagarajan; Bernadette Brennan; G Douglas Letson; Lisa A Teot; Allen Goorin; Daniel Baumhoer; Leo Kager; Mathias Werner; Ching C Lau; Kirsten Sundby Hall; Hans Gelderblom; Paul Meyers; Richard Gorlick; Reinhard Windhager; Knut Helmke; Mikael Eriksson; Peter M Hoogerbrugge; Paula Schomberg; Per-Ulf Tunn; Thomas Kühne; Heribert Jürgens; Henk van den Berg; Tom Böhling; Susan Picton; Marleen Renard; Peter Reichardt; Joachim Gerss; Trude Butterfass-Bahloul; Carol Morris; Pancras C W Hogendoorn; Beatrice Seddon; Gabriele Calaminus; Maria Michelagnoli; Catharina Dhooge; Matthew R Sydes; Mark Bernstein
Journal:  J Clin Oncol       Date:  2015-06-01       Impact factor: 44.544

Review 10.  Combination versus sequential single agent chemotherapy for metastatic breast cancer.

Authors:  Rachel F Dear; Kevin McGeechan; Marisa C Jenkins; Alexandra Barratt; Martin H N Tattersall; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2013-12-18
View more
  1 in total

1.  Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma.

Authors:  Marta Spreafico; Francesca Ieva; Francesca Arlati; Federico Capello; Federico Fatone; Filippo Fedeli; Gianmarco Genalti; Jakob Anninga; Hans Gelderblom; Marta Fiocco
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.